Brief: Trevena Pauses Enrollment In Proof-Of-Concept Clinical Trials For Trv250 And Trv734

Trevena

26/03/2020 11:26

March 26 (Reuters) - Trevena Inc  TRVN.O :
    * TREVENA - ON MARCH 26,  ANNOUNCED THAT ENROLLMENT HAS BEEN
PAUSED IN PROOF-OF-CONCEPT CLINICAL TRIALS FOR TRV250 AND TRV734
    * TREVENA - WITHDRAWING PREVIOUS GUIDANCE WITH RESPECT TO
TIMING
OF TOP LINE DATA FOR TRV250 AND TRV734
    * TREVENA - WILL ISSUE FURTHER INFORMATION REGARDING
CLINICAL
TRIALS AS IT BECOMES AVAILABLE FOR TRV250 AND TRV734
    * TREVENA - ANNOUNCED THE U.S. FDA REVIEW OF THE
RESUBMISSION OF
NDA FOR OLICERIDINE IS ONGOING
    * TREVENA - EXPECTS THE FDA’S PDUFA GOAL DATE FOR COMPLETION
OF
THE FDA’S REVIEW OF THE NDA FOR OLICERIDINE TO REMAIN AUGUST 7,
2020
    * TREVENA - COVID-19 PANDEMIC COULD MATERIALLY AFFECT
OPERATIONS,
INCLUDING AT HEADQUARTERS IN PENNSYLVANIA AND AT CLINICAL TRIAL
SITES
    * TREVENA -  CLINICAL SITE INITIATION AND PATIENT ENROLLMENT
MAY
BE DELAYED DUE TO PRIORITIZATION OF HOSPITAL RESOURCES TOWARD
THE COVID-19 PANDEMIC

Source text: https://bit.ly/2UhDiqq
Further company coverage:  TRVN.O 

 ((Reuters.Briefs@thomsonreuters.com;))